Glaukos

company

About

Glaukos is a glaucoma treatment company developing micro-bypass therapies to moderate the intraocular pressures that help preserve vision.

  • 251 - 500

Details

Last Funding Type
Series A
Last Funding Money Raised
$10M
Industries
Health Care,Medical,Wellness
Founded date
Jan 1, 1998
Number Of Employee
251 - 500
Operating Status
Active

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm.

They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide.

In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$104.50M
Glaukos has raised a total of $104.50M in funding over 2 rounds. Their latest funding was raised on Feb 7, 2013 from a Series F round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 7, 2013 Series F $30M 1 Detail
Feb 2, 2011 Series E $29.50M 1 Detail
Aug 29, 2008 Series D $35M 1 Detail
Sep 1, 2002 Series A $10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Glaukos is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Series F